Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
Duchenne muscular dystrophy (DMD) is an X-linked inherited disorder. Patients present with decreased bone mineral density (BMD) due to glucocorticoid therapy and progressive muscle weakness. Bone remodeling allows bone volume and structure to be maintained and controlled by local and systemic factor...
Saved in:
Main Authors: | Salvador Atilano-Miguel (Author), Lourdes Barbosa-Cortés (Author), Rocío Ortiz-Muñiz (Author) |
---|---|
Format: | Book |
Published: |
Permanyer,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucocorticoids for Duchenne Muscular Dystrophy
by: J Gordon Millichap
Published: (2013) -
A qualitative investigation of RANKL, RANK and OPG in a rat model of transient ankylosis
by: Curl Linda, et al.
Published: (2014) -
Baicalin Ameliorates Dexamethasone-Induced Osteoporosis by Regulation of the RANK/RANKL/OPG Signaling Pathway
by: Zhao Y, et al.
Published: (2020) -
Association of Genetic Variants of RANK, RANKL, and OPG with Ankylosing Spondylitis Clinical Features in Taiwanese
by: Chin-Man Wang, et al.
Published: (2019) -
Pangasius djambal gelatin increases osteoprotegerin, decreases RANK and RANKL after tooth extraction in vivo
by: Fredy Mardiyantoro, et al.
Published: (2023)